title: Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial.
abstract: This study's aims were to determine the efficacy and tolerability of rasagiline, a selective monoamine oxidase inhibitor B, for PD patients with mild cognitive impairment.
  
  
  
  Patients on stable dopaminergic therapy were randomized to adjunct rasagiline 1 mg/day or placebo in this 24-week, double-blind, placebo-controlled, multisite study. The primary endpoint was mean change from baseline to week 24 on the Scales for Outcomes of Parkinson's Disease-Cognition total score. Key secondary measures included changes in cognition, activities of daily living, motor scores, and Clinical Global Impression of Change, as well as safety and tolerability measures.
  
  
  
  Of the 170 patients randomized, 151 (88.2%) completed the study. Change in Scales for Outcomes of Parkinson's Disease-Cognition scores were not significantly different in the rasagiline and placebo groups (adjusted mean: 1.6 [standard error {SE} = 0.5] vs. 0.8 [SE = 0.5] points; LS means difference = 0.8; 95% confidence interval: -0.48, 2.05; P = 0.22). There were no between-group differences in change in the MoCA (p=0.84) or Penn Daily Activities Questionnaire (P = 0.48) scores or in the distribution of Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change modified for mild cognitive impairment (P = 0.1). Changes in motor (UPDRS part III; P = 0.02) and activities of daily living (UPDRS part II; P < 0.001) scores favored rasagiline. Rasagiline was well tolerated; the most common adverse events in both groups were falls and dizziness.
  
  
  
  Rasagiline treatment in PD patients with mild cognitive impairment was not associated with cognitive improvement. Rasagiline did not worsen cognition, improved motor symptoms and activities of daily living, and was well tolerated in elderly cognitively impaired patients. © 2016 International Parkinson and Movement Disorder Society.
authors.affiliation: Departments of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
authors.forename: Daniel
authors.initials: D
authors.lastname: Weintraub
authors.affiliation: University of South Florida, Tampa, Florida, USA.
authors.forename: Robert A
authors.initials: RA
authors.lastname: Hauser
authors.affiliation: Department of Public Health Science, Medical University of South Carolina, Charleston, South Carolina, USA.
authors.forename: Jordan J
authors.initials: JJ
authors.lastname: Elm
authors.affiliation: Georgetown University Medical Center, Washington, DC.
authors.forename: Fernando
authors.initials: F
authors.lastname: Pagan
authors.affiliation: Teva Pharmaceuticals, West Chester, Pennsylvania, USA.
authors.forename: Matthew D
authors.initials: MD
authors.lastname: Davis
authors.affiliation: Teva Pharmaceuticals, Overland Park, Kansas, USA.
authors.forename: Azhar
authors.initials: A
authors.lastname: Choudhry
mesh_terms: D000368:Aged; D060825:Cognitive Dysfunction / Q000188:drug therapy* / Q000209:etiology; D015259:Dopamine Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007189:Indans / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D017063:Outcome Assessment, Health Care; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy*
chemical_list: D015259:Dopamine Agents; D007189:Indans; D008996:Monoamine Oxidase Inhibitors; C031967:rasagiline
keywords: MAO; Parkinson's disease; mild cognitive impairment; rasagiline